Taiwan FDA clears GenomeFrontier’s IND application for GF-CART01, a CD20/CD19 dual targeting CAR T cell therapy for hematological B cell malignancies!

GenomeFrontier achieved a major milestone in its mission to develop innovative gene therapies and cell therapies that are affordable and therapeutically effective. On February 6, 2025, the Taiwan Food and Drug Administration ( TFDA ) cleared its Investigational New Drug ( IND ) application for GF-CART01 , a CD20/CD19-directed dual targeting CAR T cell therapy for hematological B cell malignancies. GF-CART01 will be evaluated in a Phase 1 clinical trial to be conducted in Taiwan.

The release as fetched from its publisher. genomefrontier.com ↗